Biomarin R&D day: massive patient-to-patient variability for Hemo A | SGMO Message Board Posts

Sangamo Therapeutics, Inc.

  SGMO website

SGMO   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  136580 of 140737  at  11/17/2019 9:49:43 PM  by

spaddy


 In response to msg 136575 by  civic08801
view thread

Re: Biomarin R&D day: massive patient-to-patient variability for Hemo A

 "WHAT IS YOUR ASSESSMENT RE WHAT do you think will be the consensus of the doctors re their l recommendations to their patients ?"
 
Doctors and their patients will definitely wait for SGMO product if data in December proves that BMRN is an inferior product..
 
There is good current standard of care so no need to rush for > 95% of the hemophilia population.
 


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 5     Views: 327
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board






About Us  •  Contact Us  •  Follow Us on Twitter  •  Members Directory  •  Help Center  •  Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
© 2003-2019 Investorvillage.com. All rights reserved. User Agreement
   
Financial Market Data provided by
.


Loading...